Open-label risperidone treatment of 6 children and adolescents with autism [2]

Canadian Journal of Psychiatry

Volumn 46, Issue 6, 2001, Pages 559-560

  Vercellino, F ^a   Zanotto, E ^a   Ravera, G ^a   Veneselli, E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADOLESCENT; AUTISM; BEHAVIOR MODIFICATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; HUMAN; HYPERACTIVITY; IRRITABILITY; LETTER; MALE; PSYCHIATRIC DIAGNOSIS; SCREENING TEST; SEDATION; SEIZURE; SLEEP DISORDER; SYMPTOM; WEIGHT GAIN;

EID: 0034838607     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370104600614     Document Type: Letter

References (9)

1. A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism
2. Risperidone in the treatment of pervasive developmental disorder
3. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study
4. Risperidone in young children with pervasive developmental disorders and other developmental disabilities
5. An open trial of risperidone in young autistic children
6. Clinical global impressions
7. The behavioural summarized evaluation: Validity and reliability of a scale for the assessment of autistic behaviours
8. The extrapyramidal symptom rating scale